Twelve Questions, Answered From the Cited Record

What does BPC-157 do in the body?

In animal models, it accelerates healing across a range of tissues, and the most consistently documented reason is angiogenesis — the growth of new blood vessels into an injured area. BPC157 up-regulates the VEGFR2 receptor and promotes its internalisation, activating the downstream VEGFR2-Akt-eNOS pathway; that was shown in chick chorioallantoic membrane, in rat hindlimb ischaemia, and in human vascular endothelial cells, producing higher vessel density and faster blood-flow recovery ^[4]. Secondary routes reported in the literature include FAK-paxillin signalling in cell migration, growth-hormone-receptor sensitisation in tendon fibroblasts, and modulation of the nitric-oxide system and several neurotransmitter systems ^[7].

What it does in a human body is a genuinely open question. A 2025 review found only three pilot studies in humans and concluded that rigorous large-scale trials are lacking ^[2].

Is BPC-157 a growth hormone?

No. BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Growth hormone is a 191-amino-acid protein released by the pituitary gland. They are different molecules with different origins and different receptors, and BPC-157 is not a growth hormone, a growth hormone secretagogue, or a growth hormone analogue.

The confusion has a real root, though. In cultured tendon cells BPC-157 increases growth-hormone-receptor signalling — meaning it appears to make those cells more responsive to growth hormone rather than supplying any. That mechanism is one reason tendon models respond, and it is also the basis of a standing theoretical caution: any agent nudging growth pathways raises an unanswered question about long-term effects, and no long-term human safety data exists to settle it.

Does BPC-157 work immediately?

The pharmacokinetics and the community reports point in opposite directions, which is worth seeing plainly.

On the pharmacokinetic side, formal work in rats and beagle dogs found an elimination half-life under 30 minutes, with intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism ^[3]. The molecule does not persist.

On the community side — and this is anecdotal, not clinical evidence — reports in research-use forums typically describe changes over one to three weeks rather than immediately, most often in stubborn tendon, ligament and joint complaints. No controlled human trial has measured a time course for any outcome, so there is no evidence-based answer to how long anything takes.

Does BPC-157 damage the liver?

There is no evidence in the cited record that it does, and there is also almost no evidence either way, which is the more useful thing to know.

The only relevant human data is an intravenous safety pilot in two healthy adults, dosed at up to 20 mg, which reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. Two people is not a safety dataset. It is a signal that nothing obvious happened twice.

The broader position is the one a 2025 review takes: human data are extremely limited, rigorous large-scale trials are lacking, and the compound should be treated as investigational ^[2]. Absence of a reported harm in a two-person pilot is not the same as demonstrated organ safety.

What is TB-500, and what does TB stand for?

TB stands for thymosin beta. TB-500 is a synthetic, N-terminally acetylated heptapeptide — Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH — corresponding to residues 17 to 23 of thymosin beta-4, a 43-amino-acid protein encoded by the gene TMSB4X. That seven-residue stretch, LKKTETQ, is the conserved actin-binding motif shared across the beta-thymosins.

The number 500 is a product designation, not a chemical descriptor.

The critical distinction: in commerce and in anti-doping science, "TB-500" means the roughly 889 Da heptapeptide, while the great majority of published efficacy research used full-length thymosin beta-4 at roughly 4963 Da. Whether the fragment reproduces the parent protein's effects has not been established in controlled human trials.

Does TB-500 work for muscle tears and recovery from exercise?

No controlled human trial has tested that, for the fragment or for the parent protein. What exists points in more than one direction.

Supporting the idea: the parent protein binds actin and promotes cell mobilisation and migration, decreases myofibroblast numbers and so reduces scar formation, is released by platelets and macrophages after injury, and promotes angiogenesis ^[10]. That is a coherent tissue-repair mechanism.

Cutting against it: in dystrophin-deficient mice, chronic thymosin beta-4 increased the number of regenerating muscle fibres but did not improve muscle strength, cardiac function or fibrosis. More regeneration on paper did not become better function. A 2026 sports-medicine review of unapproved peptides for musculoskeletal injuries and athletic performance concluded that animal-model promise coexists with scarce human safety data, potential for serious harm, and operation largely outside regulatory oversight ^[8].

And for any tested athlete the question is moot: TB-500 is prohibited by the World Anti-Doping Agency and anti-doping laboratories detect it and its breakdown products.

What does a GHK-Cu peptide do?

It carries copper into tissue and tells connective-tissue cells to build matrix.

At picomolar-to-nanomolar concentrations GHK-Cu stimulates dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and decorin, while rebalancing matrix metalloproteinases against their TIMP inhibitors. The copper ion itself enables lysyl-oxidase-mediated cross-linking of collagen and elastin and provides superoxide-dismutase-like antioxidant activity. Documented synthesis products include collagen, dermatan sulfate, chondroitin sulfate and decorin ^[16].

At the gene level the effect is broad: approximately 31.2% of human genes altered at a 50%-or-greater change threshold, 59% of the affected genes up and 41% down, with strong stimulation of the ubiquitin-proteasome system at 41 genes up and one down, plus DNA-repair and antioxidant gene sets ^[14].

Every one of those measurements was taken in skin cells, skin tissue or gene-expression databases.

Is GHK-Cu peptide really anti-aging?

It has the best controlled human evidence of the four compounds on this site, and that evidence is cosmetic and dermatological rather than systemic.

What is documented: topical GHK-Cu increased collagen production in 70% of treated women, against 50% for vitamin C and 40% for retinoic acid, with placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density ^[16]. A 2025 review reports procollagen synthesis increased in 70% of GHK-Cu-treated subjects on the same comparison, while identifying poor stratum-corneum permeability — clogP −2.24 — as the central delivery obstacle ^[13]. Plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[16], which is where the aging framing originates.

What is not documented: any systemic anti-aging outcome, any lifespan effect, any organ-level result. Human clinical evidence is limited to small topical trials of roughly n=13 to n=71 plus one 45-patient combination hair study ^[15], and a large share of the foundational mechanistic literature comes from a single investigator and colleagues, which limits independent replication.

What is the difference between GHK and GHK-Cu?

GHK is the bare tripeptide — glycine, histidine, lysine. GHK-Cu is that tripeptide chelated 1:1 to a copper(II) ion, coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen, with the lysine side chain left free.

The difference is functional, not cosmetic. Most of GHK-Cu's documented tissue-remodelling activity depends on the copper being properly bound; plain GHK without copper does not reproduce key effects such as MMP-2 stimulation in cell studies. The intact complex also binds copper very tightly, which prevents the metal from acting as a pro-oxidant — if a product degrades, or is mixed with a strong reducing agent such as ascorbic acid at low pH, that protective binding is lost.

The two are frequently conflated in the published literature, so the form actually used is worth checking in any study being cited.

What is KLOW peptide, and what is it used for in research?

KLOW is a co-formulated, lyophilised blend of four chemically distinct research peptides in a single vial — KPV, GHK-Cu, BPC-157 and TB-500. They are co-dissolved at fixed mass ratios and do not form a single chemical complex. The most widely listed research-vial composition across independent compounders is an 80 mg total vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg.

The stated rationale is that the four occupy non-overlapping nodes of one repair network — KPV suppressing NF-κB-driven inflammatory transcription ^[18], GHK-Cu driving matrix synthesis ^[14][16], BPC-157 driving angiogenesis ^[1], TB-500 supporting cell migration ^[8].

What it is used for in the literature is nothing, because there is no literature on it. No controlled study has tested the blend against monotherapy, against any subset, or against placebo. Some vendors additionally mislabel it as a weight-management or metabolic peptide; none of its four components is a GLP-1 or incretin agonist, and nothing in the component literature supports that framing.

How much KLOW peptide per day is used in studies?

There is no answer to give, and the absence is the point.

No controlled study of the KLOW blend exists at any dose, in any species, so there is no studied daily amount to report. The community protocols in circulation are not derived from trials. This site does not publish dosing for any compound, and would have nothing to publish here even if it did.

There is also a structural reason the question does not resolve cleanly. The four components clear at very different rates — BPC-157 has an elimination half-life under 30 minutes in formal animal pharmacokinetic work ^[3], and the tripeptides KPV and GHK-Cu clear faster still — so a single co-formulated dose cannot hold all four at matched exposures whatever the amount. There is no validated human pharmacokinetic data for injectable GHK-Cu at all, and the TB-500 fragment's kinetics are uncharacterised. A daily figure would be a number without a study behind it.

Has any of these peptides been shown to rebuild bone or cartilage?

No. This is the question the site exists to answer, and the answer is unambiguous.

Not one of the primary experiments cited across these four compounds used a bone or cartilage endpoint — no fracture model, no osteotomy, no chondral defect, no osteoarthritis outcome, no bone-density, cartilage-thickness or joint-space measurement, in any species. What the cited studies measured was gastric mucosa in rats ^[5], a transected Achilles tendon in rats ^[6], angiogenesis in chick membrane and rat hindlimb ^[4], brain function after stroke in rats ^[9], colitis in mice ^[18], gene expression and collagen synthesis in human skin cells ^[14][16], wrinkle and hair outcomes in small human topical trials ^[13][15], copper permeation through a piece of human skin ^[17], and safety in two adults ^[1] and forty volunteers ^[11].

No peptide on this site has been shown in a blinded human trial to restore cartilage. Articular cartilage is avascular and, in adults, has very little intrinsic capacity to repair itself, which is precisely why a claim of restoration would require exactly that kind of trial. The two relevant reviews say the same thing in the same direction: only three human pilot studies for BPC-157, with rigorous trials lacking ^[2], and animal-model promise alongside scarce human safety data for the wider unapproved-peptide class ^[8].